奇正藏药(002287) - 2024 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2024 reached ¥461,921,113.77, an increase of 10.92% year-over-year, while year-to-date revenue totaled ¥1,471,754,788.04, up 18.10% compared to the same period last year[1] - Net profit attributable to shareholders for Q3 2024 was ¥67,690,165.95, a decrease of 0.80% year-over-year, with year-to-date net profit at ¥393,375,922.95, reflecting a 3.38% increase[1] - The total operating revenue for Q3 2024 reached ¥1,471,754,788.04, an increase of approximately 18.1% compared to ¥1,246,236,765.94 in the same period last year[13] - The net profit for Q3 2024 was CNY 394,368,379.14, an increase from CNY 379,541,520.81 in Q3 2023, representing a growth of approximately 3.2%[14] - The total profit for the period was CNY 441,437,082.85, up from CNY 413,129,692.77, which is an increase of approximately 6.8%[14] - The comprehensive income total for the period was CNY 393,965,532.03, compared to CNY 380,662,009.78, representing an increase of approximately 3.4%[15] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥231,216,685.50, showing a significant increase of 97.57% compared to the previous year[1] - The net cash flow from operating activities for Q3 2024 was CNY 231,216,685.50, an increase of 97.4% compared to CNY 117,028,871.91 in Q3 2023[17] - The company's net increase in cash and cash equivalents was CNY -72,628,351.11, a 66.01% improvement compared to the previous period[6] - Cash and cash equivalents at the end of Q3 2024 stood at CNY 315,875,423.80, compared to CNY 223,908,002.02 at the end of Q3 2023[18] - The total cash inflow from investment activities reached CNY 1,505,376,545.28, up from CNY 1,082,864,261.66 in the same period last year[17] - The net cash flow from investment activities was -CNY 323,635,736.69, an improvement from -CNY 515,860,243.12 in Q3 2023[17] - The total cash outflow from financing activities was CNY 733,306,452.81, an increase from CNY 565,952,494.91 in Q3 2023[17] - The cash flow from financing activities showed a net increase of CNY 20,193,547.19, a decrease from CNY 184,047,505.09 in Q3 2023[17] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥6,529,757,833.30, representing a 3.67% increase from the end of the previous year[1] - The total liabilities increased to ¥2,618,993,418.29 from ¥2,528,334,499.93, marking an increase of about 3.6%[13] - Shareholders' equity attributable to the parent company reached ¥3,859,903,162.64, up 3.75% from the end of the previous year[1] Expenses - The company's operating costs increased by 39.02% to CNY 270,919,592.45 due to higher fixed asset depreciation[6] - The total operating costs for Q3 2024 were ¥1,166,221,882.87, up from ¥957,209,847.78, reflecting a year-over-year increase of about 22%[13] - Sales expenses increased to CNY 667,009,311.27 from CNY 533,538,618.18, reflecting a rise of about 25% year-over-year[14] - Research and development expenses rose to CNY 41,773,785.26, compared to CNY 40,133,818.82 in the previous year, indicating a growth of approximately 4.1%[14] - The company's income tax expenses increased by 40.13% to CNY 47,068,703.71, primarily due to the increase in deferred income tax liabilities[6] Investments and Other Income - The investment income decreased by 75.78% to CNY 10,696,306.85, reflecting reduced returns from long-term equity investments and financial products[6] - Other income increased to CNY 66,637,637.76 from CNY 55,767,051.14, reflecting a growth of about 19.5%[14] - The company's public value change income rose by 134.89% to CNY 68,211,971.04, reflecting increased fair value gains on trading financial assets[6] Shareholder Information - The company's total number of ordinary shareholders at the end of the reporting period was 20,146[7] - Gansu Qizheng Industrial Group Co., Ltd. holds a 68.76% stake in the company, with 23,913,456 shares pledged[7] Company Developments - The company completed a capital increase of ¥180 million for its subsidiary, Gansu Fogao Tibetan Medicine Co., Ltd., to support the construction and operation of the "Qizheng Tibetan Medicine Industrial Base"[10] - The company established Qizheng (Zhuhai Hengqin) International Pharmaceutical Co., Ltd. on September 25, 2024, with no capital contribution made by the report date[10] Audit Information - The company did not undergo an audit for the Q3 2024 report[18]